---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-193353"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:57:17.286781+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics appoints Misbah Tahir as CFO, effective Sep 2, 2025

## Summary
- Misbah Tahir appointed CFO, previously CFO of IGM Biosciences (Jan 2019–Aug 2025).
- Annual base salary of $500,000, discretionary bonus up to 40% of base salary.
- One-time sign-on bonus of $50,000 (clawback if service <1 year) and option for 325,000 shares.
- Option vests 25% on first anniversary, then 1/48th monthly; severance includes 9 months base salary plus benefits.
- Enhanced severance on termination without cause or for good reason within 3 months before/12 months after change in control.

## SEC filing metadata
- accession: 0001193125-25-193353
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312525193353/0001193125-25-193353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312525193353/d11864d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-193353
- JSON: https://secwatch.observer/filing/0001193125-25-193353.json
- Plain text: https://secwatch.observer/filing/0001193125-25-193353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.